Notícias Alnylam Pharmaceuticals Inc - ALNY | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (ALNY) Notícias

Alnylam Pharmaceuticals Inc (ALNY)

248,79

14,52

(6,20%)

Fechado 20 Novembro 6:00PM

Atrasado por 15 minutos

248,79

0,00

( 0,00% )

Pré-mercado: 10:22AM

Atrasado por 15 minutos

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Alnylam dépose une demande d’autorisation de mise sur le marché auprès de l’Agence européenne des médicaments pour le vutrisiran dans le cadre du traitement de l’amylose ATTR avec cardiomyopathie

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Form 4 - Statement of changes in beneficial ownership of securities

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Alnylam Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições